Aethlon Medical Announces Completion of Human Safety Study

SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc. (OTCBB:AEMD) today announced the completion of a human safety study conducted at the Fortis Hospital in Delhi, India. The primary objective of the study was to evaluate the safety of the Aethlon Hemopurifier® in health compromised end-stage renal disease (ESRD) patients that require kidney dialysis. The Hemopurifier® is a first-in-class medical device that assists the immune response in combating infectious disease through real-time therapeutic filtration of infectious viruses and immunosuppressive proteins. In addition to demonstrating safety, the study provided the opportunity to observe changes in viral load in ESRD patients infected with Hepatitis-C virus (HCV).